ClinicalTrials.gg
CompletedNCT04309916Updated Feb 25, 2022

Study to Evaluate the Efficacy and Safety of Tegoprazan in ERD Patients With Nighttime Heartburn and Sleep Disturbance

A Phase 4 interventional study of Tegoprazan and Esomeprazole in Erosive Reflux Disease, sponsored by HK inno.N Corporation. Completed at 1 site in Korea, Republic of. Open to participants aged 19 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-02-25.

Sponsored by HK inno.N Corporation · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
46
Allocation
Randomized
Ages
19 Years to 75 Years
Sex
All
01

Study summary

This study aims to compare the nighttime heartburn and sleep disturbance improvement effect of Tegoprazan 50mg and Eomeprazole 40mg in patients with ERD patients.

Read the detailed description

This is a multi-center, double-blind, randomized, active-controlled phase 4 (pilot) study. Subjects will be randomly assigned to one of the two treatment groups (tegoprazan 50mg, esomeprazole 40mg)

02

Conditions studied

  • Erosive Reflux Disease
03

In context

Lead sponsor

HK inno.N Corporation is the lead sponsor of 104 studies on the registry; 19 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
19 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects aged between 19 and 75 years
  2. Subjects who have erosive reflux disease

Exclusion criteria

Exclusion Criteria:

  1. Unable to undergo upper GI endoscopy
  2. Symptoms of primary or secondary esophageal movement disorders
  3. Planning or Perform surgery that can affect gastric acid secretion (e.g., upper gastrectomy, Vagotomy, etc.)
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
46 participants (actual)

Study arms

  • Experimental
    Tegoprazan 50mg

    Tegoprazan 50mg tablet, once daily, oral administration

    Drug: Tegoprazan

  • Active comparator
    Esomeprazole 40mg

    Esomeprazole 40mg tablet, once daily, oral administration

    Drug: Esomeprazole

Interventions

06

What researchers measure

Primary outcomes

  1. Time to first nighttime heartburn-free interval (days))

    Number of days to reach the without symptoms of nighttime heartburn after the start of drug administration for clinical trials.

    Time frame: 2 week

Secondary outcomes

  1. Percentage of days without nighttime heartburn during the 2-week dosing period

    Percentage of days without nighttime heartburn = Number of days without nighttime heartburn symptoms during the dosing period / Number of days when nighttime heartburn was assessed x 100

    Time frame: 2 week

07

Study locations

1 site
  • Severance Hospital
    Seoul, 03722, Korea, Republic of
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2020 to primary completion in Nov 2021, 18 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 13, 2020
First posted
Mar 17, 2020
StartActual
May 22, 2020
Primary completionActual
Nov 30, 2021
CompletionActual
Nov 30, 2021
Last update
Feb 25, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 25, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04309916
Responsible party
Sponsor
First posted
Mar 17, 2020
Start date
May 22, 2020
Primary completion
Nov 30, 2021
Completion
Nov 30, 2021
Last update
Feb 25, 2022

Study contacts

Sang Kil Lee, Ph.D
principal investigator · Severance Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tegoprazan

Start the discussion